Meeder Asset Management Inc. lowered its position in Masimo Co. (NASDAQ:MASI) by 19.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,303 shares of the medical equipment provider’s stock after selling 1,768 shares during the period. Meeder Asset Management Inc.’s holdings in Masimo were worth $1,010,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LPL Financial LLC lifted its position in shares of Masimo by 120.9% in the third quarter. LPL Financial LLC now owns 8,131 shares of the medical equipment provider’s stock valued at $1,013,000 after acquiring an additional 4,450 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Masimo by 4.7% during the third quarter. The Manufacturers Life Insurance Company now owns 79,577 shares of the medical equipment provider’s stock worth $9,910,000 after buying an additional 3,587 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in Masimo by 5.8% during the third quarter. Thrivent Financial for Lutherans now owns 11,489 shares of the medical equipment provider’s stock worth $1,431,000 after buying an additional 634 shares in the last quarter. AQR Capital Management LLC lifted its position in Masimo by 198.5% during the third quarter. AQR Capital Management LLC now owns 419,033 shares of the medical equipment provider’s stock worth $52,186,000 after buying an additional 278,630 shares in the last quarter. Finally, Koshinski Asset Management Inc. purchased a new position in Masimo during the third quarter worth approximately $201,000. Institutional investors and hedge funds own 83.16% of the company’s stock.
In other Masimo news, insider Jon Coleman sold 2,000 shares of Masimo stock in a transaction on Monday, April 1st. The stock was sold at an average price of $140.00, for a total value of $280,000.00. Following the sale, the insider now owns 13,201 shares in the company, valued at $1,848,140. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ramshorst David J. Van sold 1,845 shares of Masimo stock in a transaction on Monday, April 1st. The shares were sold at an average price of $140.00, for a total value of $258,300.00. Following the completion of the sale, the chief accounting officer now owns 1,695 shares in the company, valued at approximately $237,300. The disclosure for this sale can be found here. Insiders sold 33,722 shares of company stock worth $4,582,310 in the last 90 days. Company insiders own 11.50% of the company’s stock.
Masimo (NASDAQ:MASI) last posted its earnings results on Monday, May 6th. The medical equipment provider reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The company had revenue of $231.70 million for the quarter, compared to the consensus estimate of $223.67 million. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts expect that Masimo Co. will post 3.12 EPS for the current year.
MASI has been the topic of a number of analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $139.00 price objective on shares of Masimo in a research report on Friday, February 1st. BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating and set a $134.50 price objective on the stock. in a research report on Tuesday, April 16th. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 31st. Piper Jaffray Companies reiterated an “overweight” rating and set a $140.00 price objective on shares of Masimo in a research report on Wednesday, February 27th. Finally, Zacks Investment Research upgraded Masimo from a “sell” rating to a “hold” rating in a research report on Wednesday, January 16th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Masimo currently has a consensus rating of “Buy” and an average price target of $149.75.
WARNING: This piece was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/11/masimo-co-masi-shares-sold-by-meeder-asset-management-inc.html.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: What is the Rule of 72?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.